 |
|
|
| |
GS-5816, a Once-Daily NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients
With Genotype 1-4 HCV Infection in a 3 Day Monotherapy Study
|
| |
| |
Reported by Jules Levin
The Liver Meeting® 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases, November 1-5, 2013, Washington, DC
Eric Lawitz,1 Steven Glass,2 Daniel Gruener,3 Bradley Freilich,4 John Hill,5 John Link,6 Polina German,6 Hongmei Mo,6 Lingling Han,6 Diana M. Brainard,6 John McNally,6 William T. Symonds,6 William B. Smith,7 Suzanne Kim,8 Thomas Marbury,9 Jon Ruckle,10 Maribel Rodriguez-Torres11
1Texas Liver Institute, University of Texas Health Sciences Center, San Antonio, TX; 2CRI Worldwide, LLC, Marlton, NJ; 3CRI Worldwide, LLC, Philadelphia, PA; 4Kansas City Gastroenterology and Hepatology, Kansas City, MO; 5Avail Clinical Research, LLC, Deland, FL; 6Gilead Sciences, Inc., Foster City, CA;
7NOCCR, University of Tennessee Medical Center, Knoxville, TN; 8West Coast Clinical Trials, LLC, Costa Mesa, CA; 9Orlando Clinical Research Center, Orlando, FL; 10Charles River Clinical Services Northwest, Inc., Tacoma, WA; 11Fundacion De Investigacion, San Juan, Puerto Rico
|
| |
|
|
|
|
|
